Excess endothelin has been found in people with pulmonary hypertension, causing constriction in the blood vessels in the lungs. Endothelin receptor antagonists are designed to block the excess endothelin by various means.
SSc-PAH Outcomes Worse With Initial ERA. Time to clinical worsening was significantly faster with an endothelin receptor antagonist (ERA) as primary therapy for systemic sclerosis-related pulmonary arterial hypertension compared with a phosphodiesterase-5 (PDE5) inhibitor, or the combination of a PDE5 inhibitor and an ERA, researchers reported. MedPageToday, 11/02/2015.
Bosentan (Tracleer) by Actelion is proving useful for a variety of scleroderma symptoms, including pulmonary fibrosis, pulmonary hypertension, Raynaud's, and skin fibrosis. ISN.
Letairis (Ambrisentan) by Gilead is an endothelin receptor antagonist for pulmonary hypertension. ISN.
Macitentan (Opsumit) by Actelion is an oral dual endothelin receptor antagonist for pulmonary hypertension, which submitted its FDA approval application in October 2012. ISN.
Many thanks to our recent donors, Jack and Elizabeth Lewis, Chris Dokter, Margaret Roof, Network for Good, PayPal Charitable Giving Fund, United Way Snohomish and Arnold Slotkin. See ISN News for more donors. Click Here to Donate.
TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses.
We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: